Public Employees Retirement System of Ohio Buys 7,613 Shares of Insulet Co. (NASDAQ:PODD)

Public Employees Retirement System of Ohio raised its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 29.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,063 shares of the medical instruments supplier's stock after purchasing an additional 7,613 shares during the period. Public Employees Retirement System of Ohio's holdings in Insulet were worth $8,632,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in PODD. SBI Securities Co. Ltd. bought a new stake in Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Insulet in the fourth quarter worth about $42,000. SRS Capital Advisors Inc. lifted its position in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 56 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Insulet by 1,447.1% during the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 246 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Insulet by 117.3% during the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after acquiring an additional 149 shares during the last quarter.

Insider Buying and Selling

In other news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PODD. Citigroup restated a "buy" rating and issued a $380.00 target price (up from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a research note on Monday, April 28th. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Finally, Raymond James lifted their target price on shares of Insulet from $328.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $309.88.

Insulet Stock Performance

PODD stock traded down $3.09 during trading on Wednesday, reaching $323.55. 919,836 shares of the stock were exchanged, compared to its average volume of 710,674. Insulet Co. has a twelve month low of $171.61 and a twelve month high of $333.24. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $22.77 billion, a P/E ratio of 55.88, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The stock has a 50 day simple moving average of $274.57 and a 200-day simple moving average of $271.02.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same quarter last year, the company earned $0.73 EPS. The company's quarterly revenue was up 28.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.